Study wrapper · #201
Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.
Editor's note
A metabolism-and-detection study aimed at anti-doping control, not efficacy. To map how long these peptides can be caught in urine, researchers gave GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin nasally to one volunteer each, then tracked parent compounds and breakdown products over two days by mass spectrometry. This is a single-subject-per-drug design — essentially a case series for detection-window characterisation — so it establishes metabolic fate and detectability, not clinical effect. Findings: GHRP-6 was largely excreted unchanged and detectable to ~23 hours; GHRP-2 and its acids persisted to ~47 hours; hexarelin and ipamorelin were extensively metabolised. The practical point the authors stress is that detection windows depend on individual metabolism, formulation, and route. For readers, this tells us something about human pharmacokinetics but nothing about whether these compounds help any condition or are safe; the n=1-per-drug design cannot support efficacy or safety conclusions.
Plain-language abstract
This study looked at how the body breaks down and clears several growth-hormone-releasing peptides, so that anti-doping labs can know how long after use each can still be detected. All of these peptides are on the World Anti-Doping Agency banned list. One volunteer received each of five peptides — GHRP-1, GHRP-2, GHRP-6, hexarelin, and ipamorelin — through the nose, and urine was collected for two days and analysed by mass spectrometry. GHRP-1 was never found in its original form, only as breakdown fragments (one detectable up to 27 hours). GHRP-2 and its fragments were found up to 47 hours. GHRP-6 was mostly passed unchanged and detectable for about 23 hours, its fragments only 12 hours. Hexarelin and ipamorelin were broken down heavily, leaving distinctive fragments detectable even after the original compound was gone. The researchers built these markers into a routine testing method. Their main conclusion: how long a peptide can be detected depends on the individual's metabolism, the drug preparation, and how it is taken. Because only one person received each drug, the study cannot say anything about health benefits or side effects.